Estimating myocardial fibrosis in aortic stenosis using the serum collagen type I C-terminal telopeptide to matrix metalloproteinase-1 ratio

Svante Gersch; Philipp Bengel; Niels B. Paul; Susana Ravassa; Stephan von Haehling; Andreas Fischer; Elisabeth M. Zeisberg; Miriam Puls; Gerd Hasenfuβ; Moritz Schnelle

doi:10.1002/mco2.70069

MedComm ›› 2025, Vol. 6 ›› Issue (2) : e70069 DOI: 10.1002/mco2.70069

LETTER

Estimating myocardial fibrosis in aortic stenosis using the serum collagen type I C-terminal telopeptide to matrix metalloproteinase-1 ratio

Author information +

History +

PDF

Cite this article

Download citation ▾

Svante Gersch, Philipp Bengel, Niels B. Paul, Susana Ravassa, Stephan von Haehling, Andreas Fischer, Elisabeth M. Zeisberg, Miriam Puls, Gerd Hasenfuβ, Moritz Schnelle. Estimating myocardial fibrosis in aortic stenosis using the serum collagen type I C-terminal telopeptide to matrix metalloproteinase-1 ratio. MedComm, 2025, 6(2): e70069 DOI:10.1002/mco2.70069

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Puls M, Beuthner BE, Topci R, et al. Impact of myocardial fibrosis on left ventricular remodelling, recovery, and outcome after transcatheter aortic valve implantation in different haemodynamic subtypes of severe aortic stenosis. Eur Heart J. 2020; 41(20): 1903-1914.

[2]	López B, González A, Ravassa S, et al. Circulating biomarkers of myocardial fibrosis: the need for a reappraisal. J Am Coll Cardiol. 2015; 65(22): 2449-2456.

[3]	López B, Ravassa S, González A, et al. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol. 2016; 67(3): 251-260.

[4]	Ravassa S, Trippel T, Bach D, et al. Biomarker-based phenotyping of myocardial fibrosis identifies patients with heart failure with preserved ejection fraction resistant to the beneficial effects of spironolactone: results from the Aldo-DHF trial. Eur J Heart Fail. 2018; 20(9): 1290-1299.

[5]	Ravassa S, López B, Ferreira JP, et al. Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial. Eur J Heart Fail. 2022; 24(2): 321-331.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.